Detected ·
COUR Pharma
$50M—
COUR Pharma raised $50M in Series B financing led by Lumira Ventures and Roche Venture Fund, with participation from Sanofi and existing investors including T1D Fund. The proceeds will support advancement of CNP-103, their investigational antigen-specific immune tolerance therapy in Phase 2 clinical trial for type 1 diabetes.
- Website
- courpharma.com
- linkedin.com/company/courpharma
- Amount
- $50 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-06-18 20:06:55 UTC
- Signal ID
- d0f1f707-df03-42e4-83d6-3b5156066e45
As the API returns it
{
"id": "d0f1f707-df03-42e4-83d6-3b5156066e45",
"created_at": "2026-06-18T20:06:55.703030Z",
"company_name": "COUR Pharma",
"company_website_url": "courpharma.com",
"company_linkedin_url": "https://www.linkedin.com/company/courpharma",
"event_type": "funding",
"funding_amount": 50000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*COUR Pharma raised $50M in Series B financing led by Lumira Ventures and Roche Venture Fund, with participation from Sanofi and existing investors including T1D Fund. The proceeds will support advancement of CNP-103, their investigational antigen-specific immune tolerance therapy in Phase 2 clinical trial for type 1 diabetes.*"
}